Sara Buhrlage, PhD
Dana-Farber Cancer Institute
Sara Buhrlage, PhD, is an Associate Professor in Dana-Farber’s Cancer Biology Department and Harvard Medical School’s Biological Chemistry and Molecular Pharmacology Department. Her research group focuses on the development of first-in-class inhibitors and prototype drugs for deubiquitylating enzymes (DUBs) that can be utilized to pharmacologically validate members of the gene family as new targets for cancer treatment and other diseases. DUBs have garnered significant attention recently as potential therapeutic targets in the field of oncology due to their removal of degradative ubiquitin marks from cancer causing proteins.
Prior to joining as a faculty member in July 2015, Dr. Buhrlage was a professional track scientist at Dana-Farber in the medicinal chemistry core laboratory. Dr. Buhrlage completed a Doctor of Philosophy in organic chemistry in 2008, from the University of Michigan, a completed a post-doctoral fellowship at the Broad Institute.